OTCMKTS:ONCYF (ONCYF) (ONCYF) Stock Forecast, Price & News Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$0.74▼$0.8250-Day Range N/A52-Week Range$0.32▼$0.90Volume442,324 shsAverage Volume443,150 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A About (ONCYF)Oncolytics Biotech, Inc. engages in the development of immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. It offers a non-pathogenic, properietary isolate of the reovirus that induce selective tumor lysis, and promotes an inflamed tumor phenotype through innate and adaptive immune responses. The company was founded by Matthew C. Coffey and Bradley George Thompson on April 2, 1998 and is headquartered in Calgary, Canada.Read More Receive ONCYF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for (ONCYF) and its competitors with MarketBeat's FREE daily newsletter. Email Address ONCYF Stock News HeadlinesAugust 26, 2020 | prnewswire.comOncolytics Biotech® Doses First Patient in Phase 2 IRENE Study Evaluating Pelareorep-anti-PD-1 Combination Treatment in Triple-Negative Breast CancerAugust 4, 2020 | seekingalpha.comOncolytics Biotech EPS misses by $0.06May 30, 2023 | Edge On The Street (Ad)How to Invest in AI's Fast-Growing MarketThe AI market stands at $160 billion in 2023. Estimates are the AI market will grow 20-fold to $1.8 TRILLION by 2030. One little-known company is looking to win big with a new network technology no one else has. AI could explode... and soon.July 29, 2020 | www.finanznachrichten.deOncolytics Biotech to Host Conference Call to Discuss Second Quarter Financial Results and Operational HighlightsJuly 15, 2020 | www.baystreet.caNew Drug Developments and Combinations Aiding Badly Neglected Triple-Negative Breast Cancer PatientsJune 29, 2020 | markets.businessinsider.comOncolytics Biotech (ONCY) StockJune 23, 2020 | www.marketwatch.comClinical Trials for new Therapies Providing Hope for Metastatic Breast Cancer PatientsJune 23, 2020 | seekingalpha.comDosing underway in Oncolytics Bio's combination study in metastatic breast cancerMay 30, 2023 | Edge On The Street (Ad)How to Invest in AI's Fast-Growing MarketThe AI market stands at $160 billion in 2023. Estimates are the AI market will grow 20-fold to $1.8 TRILLION by 2030. One little-known company is looking to win big with a new network technology no one else has. AI could explode... and soon.June 23, 2020 | seekingalpha.comDosing underway in Oncolytics Bio combo study in breast cancerMarch 15, 2020 | www.bloomberg.comOncolytics Biotech® Announces Collaboration with Merck and Northwestern University Combining Keytruda® and REOLYSIN® in a PhMarch 5, 2020 | www.bloomberg.comOncolytics Biotech® Announces Closing of Public Offering of UnitsJune 5, 2019 | www.finanznachrichten.deOncolytics Biotech (R) to Host Conference Call to Discuss Co-Development Agreement with Pfizer and Merck KGaAApril 23, 2019 | www.finanznachrichten.deOncolytics Biotech(R) to Present at the 2019 Bloom Burton & Co. Healthcare Investor ConferenceSee More Headlines Receive ONCYF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for (ONCYF) and its competitors with MarketBeat's FREE daily newsletter. Email Address ONCYF Company Calendar Last Earnings8/06/2015Today5/30/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS Industry Pharmaceutical Preparations Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:ONCYF Previous SymbolNASDAQ:ONCY CUSIPN/A CIKN/A Webwww.oncolyticsbiotech.com Phone(403) 670-7377FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A Key ExecutivesMatthew C. CoffeyPresident, CEO, COO & DirectorKirk J. LookChief Financial OfficerThomas C HeinemanGlobal Head-Clinical Development & OperationsAndrew R. de GuttadauroGlobal Head-Business DevelopmentKey CompetitorsAbliva AB (publ)OTCMKTS:NEVPFAcusphereOTCMKTS:ACUSAddex TherapeuticsOTCMKTS:ADDXFAeolus PharmaceuticalsOTCMKTS:AOLSAffymaxOTCMKTS:AFFYView All Competitors ONCYF Stock - Frequently Asked Questions How were (ONCYF)'s earnings last quarter? (ONCYF) (OTCMKTS:ONCYF) announced its earnings results on Thursday, August, 6th. The company reported ($0.03) earnings per share for the quarter, topping analysts' consensus estimates of ($0.04) by $0.01. What is (ONCYF)'s stock symbol? (ONCYF) trades on the OTCMKTS under the ticker symbol "ONCYF." What is (ONCYF)'s stock price today? One share of ONCYF stock can currently be purchased for approximately $0.74. How can I contact (ONCYF)? (ONCYF)'s mailing address is 1167 Kensington Crescent NW Suite 210, Calgary A0, T2N 1X7. The official website for the company is www.oncolyticsbiotech.com. The company can be reached via phone at (403) 670-7377 or via email at mmoore@oncolytics.ca. This page (OTCMKTS:ONCYF) was last updated on 5/30/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding (ONCYF) Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.